A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
Status:
Completed
Trial end date:
2020-03-14
Target enrollment:
Participant gender:
Summary
Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food
Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in
Healthy Adults.